Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP) in Cancer Patients Using a Single Daily Dose for Five Days

NCT00004213 is registered in ClinicalTrials.gov with Vion Pharmaceuticals as lead sponsor.

NCT NCT00004213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP) in Cancer Patients Using a Single Daily Dose for Five Days
Lead sponsor
Vion Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
May 31, 1998
Completion date
January 31, 2008
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific